Circadian re-set repairs long-COVID in a prodromal Parkinson's parallel: a case series.
Humans
Male
Female
Parkinson Disease
/ complications
COVID-19
/ complications
Middle Aged
Aged
Adult
Phototherapy
/ methods
Prodromal Symptoms
Sleep Initiation and Maintenance Disorders
/ etiology
SARS-CoV-2
Circadian Rhythm
/ physiology
Quality of Life
Post-Acute COVID-19 Syndrome
Treatment Outcome
Circadian
Depression
Fatigue
Insomnia
Light treatment
Long-COVID
Prodromal Parkinson’s disease
Sleep
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
23 Oct 2024
23 Oct 2024
Historique:
received:
12
03
2024
accepted:
03
09
2024
medline:
23
10
2024
pubmed:
23
10
2024
entrez:
23
10
2024
Statut:
epublish
Résumé
In this case series, results from daily visual exposure to intense polychromatic light of 2000 to 4000 LUX is presented. Bright light treatment is a standard procedure for treating seasonal affective disorder and prodromal Parkinson's disease with high success. With the post-encephalitic symptoms of long-COVID closely approximating those of prodromal Parkinson's disease, we treated insomnia and sleep-related parameters in these patients, including total sleep, number of awakenings, tendency to fall back to sleep, and fatigue, to determine whether mending sleep could improve quality of life. We present three female and two male Caucasian patients aged 42-70 years with long-COVID that persisted from 12 weeks to 139 weeks after contracting coronavirus disease. A light presentation protocol was adapted for long-COVID that not only restored sleep in all patients, but also unexpectedly repaired the depression, anxiety, and cognitive changes (brain fog) as well. A robust pattern of recovery commencing 4-5 days after treatment and was maintained for weeks to months without relapse. These preliminary findings represent a novel, minimally invasive approach for managing the most debilitating symptoms of long-COVID, making it an ideal candidate for the drug hypersensitive, post-encephalitic brain. That a compromised circadian mechanism seen in Parkinson's disease may also underlie post-encephalitic long-COVID implicates a compromised role of the circadian system in these disorders.
Sections du résumé
BACKGROUND
BACKGROUND
In this case series, results from daily visual exposure to intense polychromatic light of 2000 to 4000 LUX is presented. Bright light treatment is a standard procedure for treating seasonal affective disorder and prodromal Parkinson's disease with high success. With the post-encephalitic symptoms of long-COVID closely approximating those of prodromal Parkinson's disease, we treated insomnia and sleep-related parameters in these patients, including total sleep, number of awakenings, tendency to fall back to sleep, and fatigue, to determine whether mending sleep could improve quality of life.
CASE PRESENTATION
METHODS
We present three female and two male Caucasian patients aged 42-70 years with long-COVID that persisted from 12 weeks to 139 weeks after contracting coronavirus disease.
CONCLUSION
CONCLUSIONS
A light presentation protocol was adapted for long-COVID that not only restored sleep in all patients, but also unexpectedly repaired the depression, anxiety, and cognitive changes (brain fog) as well. A robust pattern of recovery commencing 4-5 days after treatment and was maintained for weeks to months without relapse. These preliminary findings represent a novel, minimally invasive approach for managing the most debilitating symptoms of long-COVID, making it an ideal candidate for the drug hypersensitive, post-encephalitic brain. That a compromised circadian mechanism seen in Parkinson's disease may also underlie post-encephalitic long-COVID implicates a compromised role of the circadian system in these disorders.
Identifiants
pubmed: 39438926
doi: 10.1186/s13256-024-04812-9
pii: 10.1186/s13256-024-04812-9
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
496Informations de copyright
© 2024. The Author(s).
Références
Bloem B, Okun M, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284–303.
pubmed: 33848468
doi: 10.1016/S0140-6736(21)00218-X
Mantovani S, Smith S, Gordon R, et al. An overview of sleep and circadian dysfunction in Parkinson’s disease. J Sleep Res. 2018;27(3): e12673.
pubmed: 29493044
doi: 10.1111/jsr.12673
Fifel K, De Boer T. The circadian system in Parkinson’s disease, multiple systems atrophy and progressive Supranuclear palsy. Handb Clin Neurol. 2021;179:301–13.
pubmed: 34225971
doi: 10.1016/B978-0-12-819975-6.00019-4
Li W, Chan L, Chao Y, et al. Parkinson’s disease following COVID-19: causal link or chance occurrence? J Transl Med. 2020;18:493.
pubmed: 33375935
pmcid: 7770740
doi: 10.1186/s12967-020-02670-9
Fifel K, Videnovic A. Chronotherapies for Parkinson’s disease. Prog Neurobiol. 2019;174:16–27.
pubmed: 30658126
pmcid: 6377295
doi: 10.1016/j.pneurobio.2019.01.002
Willis G. Parkinson’s disease as a neuroendocrine disorder of circadian function: dopamine–melatonin imbalance and the visual system in the genesis and progression of the degenerative process. Rev Neurosci. 2008;19(4–5):245–316.
pubmed: 19145986
Fifel K, Videnovic A. Light therapy in Parkinson’s disease: towards mechanism-based protocols. Trends Neurosci. 2018;41(5):252–4.
pubmed: 29588060
pmcid: 5924622
doi: 10.1016/j.tins.2018.03.002
Liu Z, Ting S, Zhuang X. COVID-19, circadian rhythms and sleep: from virology to chronobiology. Interface Focus. 2021;11(6):20210043.
pubmed: 34956600
pmcid: 8504895
doi: 10.1098/rsfs.2021.0043
Lewy A, Ahmed S, Jackson J, et al. International society of chronobiology: melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int. 1992;9(5):380–92.
pubmed: 1394610
doi: 10.3109/07420529209064550
Willis G, Boda J, Freelance C. Polychromatic light exposure as a therapeutic in the treatment and management of Parkinson’s disease: a controlled exploratory trial. Front Neurol. 2018;9:741.
pubmed: 30778331
pmcid: 6156259
doi: 10.3389/fneur.2018.00741
Willis G, Armstrong S. Fine-tuning the circadian system with light treatment for Parkinson’s disease: an in-depth critical review. Rev Neurosci. 2023;35(1):57–84.
pubmed: 37609845
doi: 10.1515/revneuro-2023-0026
Khatoon F, Prasad K, Kumar V. COVID-19 associated nervous system malfunctions. Sleep Med. 2022;91:231–6.
pubmed: 34321155
doi: 10.1016/j.sleep.2021.07.005
Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23(2):194–202.
pubmed: 35105985
pmcid: 9127978
doi: 10.1038/s41590-021-01104-y
Liu Y, Niu L, Liu X, et al. Recent progress in non-motor features of Parkinson’s disease with a focus on circadian rhythm dysregulation. Neurosci Bull. 2021;37(7):1010–24.
pubmed: 34128188
pmcid: 8275711
doi: 10.1007/s12264-021-00711-x
Beauchamp L, Finkelstein D, Bush A, et al. Parkinsonism as a third wave of the COVID-19 pandemic. J Park Res. 2020;10(4):1343–53.
Hood S, Amir S. The aging clock: circadian rhythms and later life. J Clin Invest. 2017;127(2):437–46.
pubmed: 28145903
pmcid: 5272178
doi: 10.1172/JCI90328
Cartella S, Terranova C, Rizzo V, et al. COVID-19 and Parkinson’s disease: an overview. J Neurol. 2021;268(12):4415–21.
pubmed: 34313818
pmcid: 8313415
doi: 10.1007/s00415-021-10721-4
Leng Y, Blackwell T, Cawthon P, et al. Association of circadian abnormalities in older adults with an increased risk of developing Parkinson disease. JAMA Neurol. 2020;77(10):1270–8.
pubmed: 32539075
pmcid: 7296450
doi: 10.1001/jamaneurol.2020.1623
Willis G, Moore C, Armstrong S. A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease. Rev Neurosci. 2012;23(2):199–226.
pubmed: 22499678
doi: 10.1515/revneuro-2011-0072
Lewy A, Sack R, Singer C. Immediate and delayed effects of bright light on human melatonin production: shifting “dawn” and “dusk” shifts the dime light melatonin onset (DLMO). Ann N Y Acad Sci. 1985;453:253–9.
pubmed: 3865585
doi: 10.1111/j.1749-6632.1985.tb11815.x
Lewy A, Rough J, Songer J, et al. The phase shift hypothesis for the circadian component of winter depression. Dialogues Clin Neurosci. 2007;9(3):291–300.
pubmed: 17969866
pmcid: 3202495
doi: 10.31887/DCNS.2007.9.3/alewy
Willis G. Common circadian features of the 1919 and COVID19 pandemics: the long-COVID and prodromal Parkinson’s parallel. 2023 (Submitted 2023).
Willis G, Turner J. Primary and secondary features of Parkinson’s disease improve with strategic exposure to bright light: a case series study. Chronobiol Int. 2007;24(3):521–37.
pubmed: 17612949
doi: 10.1080/07420520701420717
Artemenko AR, Leven L. The phototherapy for Parkinson’s patients. Zh Nevrol Psikhiatr Im SS Korsakova. 1996;96:63–6.
Martino K, Freelance C, Willis G. The effect of light exposure on insomnia and nocturnal movement in Parkinson’s disease: an open label, retrospective, longitudinal study. Sleep Med. 2018;44:24–31.
pubmed: 29530365
doi: 10.1016/j.sleep.2018.01.001
Paus S, Schmitz-Hübsch T, Wüllner U, et al. Bright light therapy in Parkinson’s disease: a pilot study. Mov Disord. 2007;22(10):1495–8.
pubmed: 17516492
doi: 10.1002/mds.21542
Videnovic A, Klerman E, Wang W, et al. Timed light therapy for sleep and daytime sleepiness associated with Parkinson’s disease: a randomised clinical trial. JAMA Neurol. 2017;74(4):411–8.
pubmed: 28241159
pmcid: 5470356
doi: 10.1001/jamaneurol.2016.5192
Massey D, Mitsuaki S, Baker AD, et al. Characterisation of internal tremors and vibration symptoms. BMJ Open. 2023;13(12): e077389.
pubmed: 38154880
pmcid: 10759066
doi: 10.1136/bmjopen-2023-077389
Rutten S, Vriend C, Smit J, et al. Bright light therapy for depression in Parkinson’s disease: a randomised controlled trial. Neurology. 2019;92(11):e1145–56.
pubmed: 30770426
doi: 10.1212/WNL.0000000000007090
Makhoul K, Jankovic J. Parkinson’s disease after COVID-19. J Neurol Sci. 2021;422: 117331.
pubmed: 33540185
pmcid: 9755718
doi: 10.1016/j.jns.2021.117331
Zarifkar P, Peinkhofer P, Benros M, et al. Frequency of neurological diseases after COVID-19, Influenza A/B and bacterial pneumonia. Front Neurol. 2022;13: 904796.
pubmed: 35812108
pmcid: 9259944
doi: 10.3389/fneur.2022.904796
Sulser D, Antonini A, Leta V, et al. COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside. NPJ Park Dis. 2020;6(1):18.
doi: 10.1038/s41531-020-00123-0
Sacks O. Awakenings. London: Picador; 1973.
Musiek E, Holtzman D. Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science. 2016;354(6315):1004–8.
pubmed: 27885006
pmcid: 5219881
doi: 10.1126/science.aah4968
Chen S, Prettner K, Kuhn M, et al. Climate and the spread of COVID-19. Sci Rep. 2021;11(1):9042.
pubmed: 33907202
pmcid: 8079387
doi: 10.1038/s41598-021-87692-z
de Pedro Cuesta J. Studies of the prevalence of paralysis agitans by tracer methodology. Acta Neurol Scand Suppl. 1987;112:1–106.
pubmed: 3303809
de Pedro CJ, Stawiarz L. Parkinson’s disease incidence: magnitude, comparability, time trends. Acta Neurol Scand. 1991;84:382–8.
doi: 10.1111/j.1600-0404.1991.tb04974.x
Chen H, Schernhammer E, Schwarzchild M, et al. A prospective study of night shift work, sleep duration and risk of Parkinson’s disease. Am J Epidemiol. 2021;163:726–30.
doi: 10.1093/aje/kwj096
Nakano T, Chiang K, Chen C, et al. Sunlight exposure and phototherapy: perspectives for healthy aging in an era of COVID-19. Int J Environ Res Public Health. 2021;18(20):10950.
pubmed: 34682694
pmcid: 8535353
doi: 10.3390/ijerph182010950
Golombek D, Pandi-Perumal S, Rosenstein R, et al. Dysregulated dark/light cycle impairs sleep and delays the recovery of patients in intensive care units: a call for action for COVID-19 treatment. Chronobiol Int. 2022;39(7):903–6.
pubmed: 35491759
doi: 10.1080/07420528.2022.2056477
Monoz-Gonzalez C, Ruiz-Jaramillo J, Cuerdo-Vilches T, et al. Natural lighting in historic houses during times of pandemic. The case of housing in the Mediterranean climate. Int J Environ Res Public Health. 2021;18(14):7264.
doi: 10.3390/ijerph18147264
Megna M, Marasca C, Fabbrocini G. Ultraviolet radiation, vitamin D and COVID-19. Ital J Dermatol Venerol. 2021;156(3):366–73.
pubmed: 33913665
Soheilifar S, Fathi H, Naghdi N. Photobiomodulation therapy as a high potential treatment modality for COVID-19. Lasers Med Sci. 2021;36(5):935–8.
pubmed: 33241526
doi: 10.1007/s10103-020-03206-9
Sabino C, Ball A, Baptista M, et al. Light-based technologies for management of COVID-19 pandemic crisis. J Photochem Photobiol B. 2020;212: 111999.
pubmed: 32855026
pmcid: 7435279
doi: 10.1016/j.jphotobiol.2020.111999
Leta V, Boura I, van Wamelen D, et al. Covid-19 and Parkinson’s disease: acute clinical implications, long-COVID and post-COVID-19 parkinsonism. Int Rev Neurobiol. 2022;165:63–89.
pubmed: 36208907
pmcid: 9357514
doi: 10.1016/bs.irn.2022.04.004
Rota R, Boura I, Wan Y, et al. Spotlight on non-motor symptoms and COVID-19. Int Rev Neurosci. 2022;165:103–33.
Endo T, Matsumura R, Tokuda I, et al. Bright light improves sleep in patients with Parkinson’s disease: possible role of circadian restoration. Sci Rep. 2020;10(1):7982.
pubmed: 32409683
pmcid: 7224174
doi: 10.1038/s41598-020-64645-6
Fertl E, Auff E, Dopplebauer A, et al. Circadian secretion pattern of melatonin in Parkinson’s disease. J Neural Transm. 1991;3:41–7.
doi: 10.1007/BF02251135
Wescott D, Wallace M, Hasler B, et al. Sleep and circadian rhythm profiles in seasonal depression. Psychiatr Res. 2022;156:114–21.
doi: 10.1016/j.jpsychires.2022.10.019
Lim R, Wambier C, Goren A. Are night shift workers at an increased risk for COVID-19? Med Hypothesis. 2020;144: 110147.
doi: 10.1016/j.mehy.2020.110147
Ricter K, Kellner S, Hillemacher T, et al. Sleep quality and COVID-19 outcomes: the evidence-based lessons in the framework of predictive, preventive and personalised (3p) medicine. EPMA J. 2021;12(2):221–41.
doi: 10.1007/s13167-021-00245-2
Pillai J, Bonner-Jackson A, Floden D, et al. Lack of accurate self-appraisal is equally likely in MCI from Parkinson’s disease and Alzheimer’s disease. Mov Disord Clin Prac. 2018;5(3):283–9.
doi: 10.1002/mdc3.12606
Brown G, Pandi-Perumal S, Pupko H, et al. Melatonin as an add-on treatment of COVID-19 infection: current status. Diseases. 2021;9(3):64.
pubmed: 34562971
pmcid: 8482145
doi: 10.3390/diseases9030064
Brusco L, Cruz P, Cangas A, et al. Efficacy of melatonin in non-intensive care unit patients with COVID-19 pneumonia and sleep dysregulation. Melatonin Res. 2021;4(1):173–88.
doi: 10.32794/mr11250089
Cardinali D, Brown G, Pandi-Perumal S. Can melatonin be a potential “silver bullet” in treating COVID-19 patients? Diseases. 2020;8(4):44.
pubmed: 33256258
pmcid: 7709121
doi: 10.3390/diseases8040044
Wong AC, Devason A, Umana I, et al. Serotonin reduction in post-acute sequelae of viral infection. Cell. 2023;186:4851–67.
pubmed: 37848036
pmcid: 11227373
doi: 10.1016/j.cell.2023.09.013
Krashner N, Cornelius J. L-dopa for post-encephalitic parkinsonism. Br Med J. 1970;4(5733):496.
doi: 10.1136/bmj.4.5733.496
Rus C, de Vries B, de Vries E, et al. Treatment of 95 post-COVID patients with SSRIs. Sci Rep. 2023;13:18599.
pubmed: 37919310
pmcid: 10622561
doi: 10.1038/s41598-023-45072-9
Abreu G, Aguilar M, Covarrubias D, et al. Amantadine as a drug to mitigate the effect of COVID 19. Med Hypothesis. 2020;140: 109755.
doi: 10.1016/j.mehy.2020.109755
Anwar F, Naqvi S, Al-Abbasi F, et al. Targeting COVID-19 in Parkinson’s patients: drugs repurposed. Curr Med Chem. 2021;28(12):2392–408.
pubmed: 32881656
doi: 10.2174/0929867327666200903115138
an het Rot M, Benkelfat C, Boivin D, et al. Bright light exposure during acute tryptophan depletion prevents a lowering of mood in mildly seasonal women. Eur Neuropsychopharmacol. 2007;18(1):14–23.
doi: 10.1016/j.euroneuro.2007.05.003
Lewy A, Emens J, Sack R, et al. Low, but not high, doses of melatonin entrained a free-running blind person with a long circadian period. Chronobiol Int. 2002;19(3):649–58.
pubmed: 12069043
doi: 10.1081/CBI-120004546
Lin L, Du Y, Yuan S, et al. Serum melatonin is an alternative index of Parkinson’s disease severity. Brain Res. 2014;1547:43–8.
pubmed: 24384141
doi: 10.1016/j.brainres.2013.12.021
Meng T, Zheng Z, Tiu T, et al. Contralateral retinal dopamine decrease and melatonin increase in progression of hemi-Parkinsonian rat. Neurochem Res. 2012;37(5):1050–6.
pubmed: 22252727
doi: 10.1007/s11064-012-0706-4
Willis G, Robertson A. Recovery of experimental Parkinson’s disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor. Pharmacol Biochem Behav. 2004;79(3):413–29.
pubmed: 15582013
doi: 10.1016/j.pbb.2004.08.011
Willis G, Robertson A. Recovery of experimental Parkinson’s disease in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine treated marmoset with the melatonin analogue ML-23. Pharmacol Biochem Behav. 2005;80(1):9–26.
pubmed: 15652376
doi: 10.1016/j.pbb.2004.10.022
Sacks O, Kohl M, Schwartz W, et al. Side-effects of L-dopa in post-encephalic parkinsonism. Lancet. 1970;1(7654):1006.
pubmed: 4191927
doi: 10.1016/S0140-6736(70)91137-2
Sacks O, Messeloff C, Schwartz W. Long-term effects of levodopa in the severely disabled patient. JAMA. 1970;213(13):2270.
pubmed: 5468938
doi: 10.1001/jama.1970.03170390060017
Mahlknecht P, Seppi K, Poewe W. The concept of prodromal Parkinson’s disease. J Park Dis. 2015;5:681–97.
Li T, Cheng C, Jai, et al. Peripheral clock system abnormalities in patients with Parkinson’s disease. Front Aging Neurosci. 2021;13: 736026.
pubmed: 34658839
pmcid: 8519399
doi: 10.3389/fnagi.2021.736026
Naik R, Avula S, Palleti S, et al. From emergence to endemicity: a comprehensive review of COVID-19. Cureus. 2023;15(10): e48046.
pubmed: 37916248
pmcid: 10617653